Abstract: Norovirus (NoV) genotype GII.4 is responsible for the majority of NoV infections causing pandemics every few years. A NoV virus-like particle (VLP)-based vaccine should optimally cover the high antigenic variation within the GII.4 genotype. We compared the immune responses generated by VLPs of the ancestral GII.4 1999 strain (GII.4 1995/96 US variant) and the most recent GII.4 Sydney 2012 pandemic strains in mice. No significant differences were observed in the type-specific responses but GII.4 1999 VLPs were more potent in inducing high-avidity antibodies with better cross-reactivity.
Introduction
Norovirus (NoV) GII.4 is the predominating NoV genotype, causing up to 85% of acute gastroenteritis outbreaks of NoV and sporadic infections worldwide [1] . It is associated with more severe clinical manifestations than other NoV genotypes [2, 3] . NoV genogroup II (GII) and GI together comprise of over 28 genetically divergent NoV genotypes infecting humans [4] . The predominance of GII.4 for over two decades is associated with several factors including fast replication and effective person-to-person transmission rates [5, 6] . In addition, GII.4 variants recognize a wide range of mucosal polysaccharides [7] and histo-blood group antigens (HBGAs), which are thought to facilitate NoV entry and/or infection [8, 9] .
The NoV particle consists of 90 dimers of capsid VP1 protein organized in T = 3 icosahedral symmetry [10] . VP1 is divided into two main domains: the shell (S) and the protruding (P) domains, the latter of which is further subdivided into P1 and P2 domains [10] . The outermost P2 domain contains the conserved HBGA binding sites but the regions surrounding these sites are evolving due to constant immune pressure [11] . NoV vaccine development is largely based on NoV virus-like particles (VLPs) [12] [13] [14] , antigenically identical to the virus particle, despite recent progress in cultivating NoV in vitro [15] .
GII. 4 NoV undergoes epochal evolution similar to influenza virus; periods of stasis lead into rapid antigenic drift in common structural epitopes that are under immune pressure [16, 17] . NoV-specific serum antibodies that block binding of NoV VLPs to HBGAs in a surrogate neutralization assay are the best correlate of protection identified so far [18] [19] [20] . Antigenic drift driven by these antibodies can lead the evolving strains gaining new HBGA binding abilities and/or escaping from previously gained immunity [21] [22] [23] . There are at least six (A-F) evolving "blocking epitopes" described [21, [23] [24] [25] and the emergence of a new GII.4 pandemic strain is typically associated with mutations in these epitopes [23, 24, 26] . Since the 1990s seven pandemics have been caused by GII. [1] .
Virions are dynamic structures reacting to environment with conformational changes, which enable biologically relevant functions such as receptor/ligand binding [27] . Mutations in the virion core, or neutralizing antibody binding to certain epitopes, can sterically block receptor binding site or cause conformational change in distant epitopes impairing ligand interactions [27] [28] [29] . Some of the highly variable blocking epitopes of NoV GII.4 are exposed on the surface of P2-domain (e.g., epitopes A and D) while others, like epitope F, are buried and broadly conserved [25] . Epitope F is considered a universal GII.4 blocking epitope, as monoclonal antibody specific to epitope F has been shown to cross-block a panel of time-ordered GII.4 VLPs [30] . Amino acids 310, 316, 484, and 493 comprise "the NERK motif", which has been suggested to limit antibody access to epitope F [31] .
In this study we investigated type-specific and cross-reactive humoral and cellular immune responses induced in mice with the first (GII.4 1999, a 1995/96 US variant) and the latest (GII.4 Sydney, 2012) pandemic GII.4 variant VLPs. In addition, we studied the effect of an amino acid mutation in the NERK motif on cross-blocking antibody responses. The results presented here add to the current knowledge and understanding of cross-reactive immune responses induced in vivo by different variant GII.4 VLPs.
Materials and Methods

NoV VLPs
Three different NoV GII.4 variant VLPs were used as immunogens and/or in vitro antigens in this study. GII.4 1999 (original patient sequence isolated in 1999; it has one amino acid difference (aa 333) to the VP1 sequence of the reference strain GII.4 1995/96 US, Genbank accession number AF080551) and GII.4 2012 (accession number AFV08795.1) VLPs were produced in baculovirus-insect cell system and purified as previously described by our laboratory [32] [33] [34] . GII.4 2006 variant VLPs (accession number BAG70446) were produced by Icon Genetics Gmbh (Halle, Germany) [35] and were utilized in analytical methods only. The epitope-engineered GII.4 2012 pFastBac1-vector with amino acid D310 substituted to N310 was ordered from GeneArt (Thermo Fisher Scientific, Waltham, MA, USA) and expressed using the Bac-to-Bac Baculovirus Expression System (Invitrogen, Carlsbad, CA, USA) as described before [32] . Mutant VLPs (referred as GII.4 2012 D310N) were produced and purified with the same methodology as the wild-type VLPs. The identity, purity, and morphology [36, 37] of the VLPs were confirmed as described elsewhere [32, 33, 38] .
Mouse Immunizations and Tissue Collections
Seven-week-old female BALB/c OlaHsd mice obtained from Envigo RMS BV (Horst, the Netherlands) were immunized intramuscularly (IM) twice (weeks 0 and 3) with 10 µg of GII.4 1999 (5 mice) or GII.4 2012 VLPs (4 mice). Mice receiving carrier buffer only (phosphate buffered saline, PBS) were used as negative controls (5 mice). Whole blood and lymphoid tissue were collected at the time of euthanization on study week 5. For bone marrow-derived dendritic cell (BMDC) generation, femurs and tibia were collected from naive control mice and the exterior tissues were sterilized with 70% ethanol and kept on ice until bone marrow extraction (described in Section 2.6). Serum was separated by centrifugation and splenocyte suspensions of each mice were prepared according to earlier published methods [38] . All procedures were authorized and performed in concordance with the guidelines by the Finnish National Animal Experiment Board (permission number ESAVI/10800/04.10.07/2016).
IgG Titer and Avidity Assay
Antigen-specific and cross-reactive immunoglobulin G (IgG) responses in mice sera were measured by enzyme-linked immunosorbent assay (ELISA) as described in detail elsewhere [32, 38] . Individual sera were added by decreasing two-fold dilutions (IgG titer determination) or 1:100 dilution (avidity assay) on 96-well half-area polystyrene plates (Corning Inc., Corning, NY, USA) coated overnight at 4 • C with NoV VLPs (1 µg/mL) and blocked for one hour at room temperature (RT) with 2% skimmed milk in PBS/0.05%Tween. After serum incubation, the bound antibodies were detected by goat anti-mouse IgG-HRP (dilution 1:6000, Sigma-Aldrich, Saint Louis, MO, USA) reacting with o-phenylenediamine dihydrochloride (OPD)-substrate (30 min RT). All incubations were performed at 37 • C for one hour unless otherwise stated. After stopping the substrate reaction with 2M H 2 SO 4 the optical density (OD) was measured at 490 nm (Victor2 1420; PerkinElmer, Waltham, MA, USA). Each sample/dilution was assayed in duplicate wells and sample volumes were 50 µL/well. The background signal from wells lacking serum (blank wells) was subtracted from all of the OD readings at a plate. The cut-off value was calculated as mean OD + 3 × SD of negative control mice sera at a given dilution. A sample resulting in an OD value above the set cut-off OD and at least 0.100 OD was considered positive. End-point antibody titers were defined as the highest dilution of serum giving an OD above the set cut-off value. Geometric mean titers (GMTs) with 95% confidence intervals (CIs) for each immunization group were counted from individual mice end-point titers.
Serum IgG avidity was measured by ELISA as described above, but after serum incubation the plates were incubated twice (for 5 min for each treatment) with 8 M urea (Sigma-Aldrich) to elute low-avidity antibodies [39] . The avidity index was calculated as (OD with urea/OD without urea) × 100%.
Carbohydrate Binding Assays
HBGA binding of mutated GII.4 2012 D310N VLPs in comparison to wild-type GII.4 2012 VLPs was analyzed by using three different sources of HBGAs: human type A saliva [7, 40] , pig gastric mucin (PGM, type III, Sigma-Aldrich) [41, 42] , and synthetic biotinylated HBGAs (Lewis a , Lewis b , H-type-1, H-type-3, A-trimer, and B-trimer, Glycotech, Gaithersburg, MD, USA) [7, 18] . Briefly, saliva (at dilution 1:3000, o/n 37 • C) or PGM (2.5 µg/mL, o/n RT) were used to coat half-area 96-well plates (Corning) and synthetic biotinylated carbohydrates (2.5 µg/mL, 1 h RT) were used on precoated NeutrAvidin plates (Pierce, Rockford, MI, USA). VLPs were added on the plates with final concentration of 0.1 µg/mL for 1.5 h (saliva and PGM plates) or 0.4 µg/mL for 2 h (synthetic HBGA plates). The bound VLPs were detected with human GII.4-positive serum following horseradish peroxidase (HRP)-conjugated anti-human IgG secondary antibody (Novex, Invitrogen) incubation (1 h). After coating, saliva plates were incubated at 37 • C, PGM plates at RT, and synthetic HBGA plates at 4 • C according to the temperatures used in the original publications [18, 40, 41] . The plates were developed and stopped as described in Section 2.3 for ELISA procedures. Positive reactivity is defined as a mean OD >0.2 after background subtraction. Each sample was tested in 2-4 replicate wells and results are represented as mean OD from parallel wells.
Blocking Assays
Blocking assay was used to measure antibodies that block binding of NoV VLPs to HBGAs present in human saliva (type A) or PGM, or to synthetic biotinylated H-type-1 carbohydrate as previously described [7, 42] . NoV VLPs with final concentration of 0.1 µg/mL (saliva and PGM assays) or 0.4 µg/mL (synthetic HBGA assays) were preincubated for 1 h at 37 • C in low binding tubes with decreasing concentration of mice serum (starting at 1:100 serum dilution for homologous and 1:20 for cross-blocking assays). The pre-incubated VLP-serum mixtures were then added on saliva, PGM, or synthetic H-type-1 coated plates, and the bound VLPs were detected with human GII.4-positive serum (for GII.4 1999 and GII.4 2012 VLP detection) or rabbit NoV-hyperimmune serum (for GII.4 2006 VLP detection) following the corresponding HRP-conjugated secondary antibody incubation. The incubation times and temperatures were the same as described in Section 2.4 for VLP-binding assays. The plates were developed, stopped, and measured as described in Section 2.3. Wells incubated with VLPs lacking mouse sera were used to determine the maximum binding OD. The blocking index (%) was calculated as 100% − [(OD wells with VLP − serum mix/OD maximum binding OD) × 100%]. The blocking titer 50 (BT50) value represents the highest serum dilution blocking 50% of the maximum VLP binding. The results are expressed as the mean blocking indexes of individual mice or the mean of replicas or repeated experiments if pooled group sera were used.
BMDC Generation and Pulsing
The method for generating mouse BMDCs was adapted from a published procedure [43] with some modifications. After removing soft tissue, the femurs and the tibiae were cut from each end with scalpel and flushed with ice cold PBS. The extracted bone marrows were passed through a 70-µm cell strainer (Becton-Dickinson, BD, Franklin Lakes, NJ, USA) and collected in complete medium (CM, RPMI-1640 supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, 50 µm 2-mercaptoethanol, 2 mm l-glutamine, and 10% fetal bovine serum (FBS), all purchased from Sigma-Aldrich). The cell suspensions were centrifuged 300× g for 10 min and suspended in CM containing 20 ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF, Abcam, Cambridge, UK). BM-cells were seeded at 1×10 6 cells/mL (10 mL per plate) in non-treated 90 × 14.2-mm sterile petri dishes (VWR, Radnor, PA, US) and cultured at 37 • C, 5% CO 2 for 8 days. Fresh CM with GM-CSF (5 mL/plate) was added on the dishes on days 4 and 7 and the cells were harvested on day 8. The generated cells were surface stained with phycoerythrin (PE)-conjugated anti-mouse CD11c and Horizon Viability Stain 780 (both from BD) and acquired using BD FACSCanto II flow cytometer as described earlier [44] which confirmed the cells to be >90% CD11c+ cells. The BMDCs were frozen according to published procedure [45] in ice-cold CM containing 10% DMSO (Sigma-Aldrich).
The BMDCs were thawed, washed twice (300× g, 10 min) and seeded 2×10 6 cells/mL in CM in non-treated cell-culture 24-well plates (Corning Costar) for antigen pulsing. GII.4 1999, GII.4 2012 and GII.4 2006 VLPs were added to the cells at 100 µg/mL. Cells lacking pulsing antigen (un-pulsed BMDCs) were used as a negative control. The cells were incubated (37 • C, 5% CO 2 ) for 20-22 hours, washed twice, and were used as antigen-presenting cells (APCs) in enzyme-linked immunospot (ELISPOT) assay.
ELISPOT-Interferon Gamma (IFN-γ)
Homologous and cross-reactive T-cell responses were analyzed by quantification of IFN-γ production from group-wise pooled mice splenocytes in response to VLP pulsed BMDCs by an ELISPOT-IFN-γ assay [36, 38] . Briefly, 96-well MultiScreen HTS-IP filter plates (Millipore, Billerica, MA, USA) were coated overnight at 4 • C with anti-mouse IFN-γ (Mabtech Ab, Nacka Strand, Sweden). After washing and blocking the plates with 10% FBS in CM (2-3 h RT), GII.4 1999, GII.4 2012, GII.4 2006 VLP pulsed or un-pulsed BMDCs (5000, 20,000, and 40,000 BMDCs/well) were added on plates. Concanavalin A (ConA; Sigma-Aldrich) at 10 µg/ml was used as a positive control to stimulate IFN-γ production from splenocytes. GII.4 1999 or GII.4 2012 VLP-immunized mice splenocytes were thawed, washed, and added to the plates (0.2 × 10 6 cells/well) on top of BMDCs and the plates were incubated for 20 h at 37 • C and 5% CO 2 . Thereafter, the cells were discarded and the plates were developed with biotinylated anti-mouse IFN-γ monoclonal antibody (0.5 µg/mL in PBS/0.5% FBS, 2 h at RT) and alkaline-phosphatase (ALP) conjugated streptavidin (1:1000, 1 h at RT) reacting with BCIP/NBT substrate (all from Mabtech). After 12 minutes the color reaction was stopped with tap water. The spots were counted by an ImmunoSpot ® automatic CTL analyzer (CTL-Europe GmbH, Bonn, Germany) and the results are expressed as mean spot forming cells (SFCs) per 10 6 live splenocytes of replicate wells.
Statistics
The Kruskal-Wallis' test was used to assess the statistical differences in antibody titers and avidity indices between individual immunization groups. A statistically significant difference was defined as a p-value of <0.05. Data were analyzed with IBM SPSS Statistics version 25.0 (SPSS Inc., Chicago, IL, USA).
Results
NoV GII.4 Type-Specific and Cross-Reactive IgG Antibody Titers and Avidity
Immunized mice sera were tested using ELISA to quantify type-specific and cross-reactive IgG antibodies against GII. Serum of mice receiving phosphate buffered saline (PBS) (5 mice) was used as a negative control (Ctrl). Shown are the geometric mean titers (GMTs) with 95% confidence intervals (error bars) counted from individual mice end-point titers in each immunization group. The dashed line illustrates the cut-off titer for samples considered positive. The avidity of IgG antibodies was measured from individual mice sera against homologous and heterologous NoV VLPs (b) as described in the Material and Methods. Horizontal lines in the box plots represent the medians, cross-symbols (×) represent the means, and the boxes illustrate the interquartile range that contains 50% of values with whiskers extending to the highest and lowest values. The antigen-specific antibody titers and the avidity indexes between immunization groups were compared by the Kruskal-Wallis test and significant differences (p value <0.05) are identified with an asterisk (*).
Comparison of the avidity of type-specific and cross-reactive antibodies are shown in Figure 1b. A remarkable difference was observed in the type-specific avidities elicited by GII.4 1999 and GII.4 2012 VLPs (Figure 1b) . GII.4 1999 VLPs induced type-specific IgG antibodies with high avidity (mean avidity index 85.7 ± 9%), whereas GII.4 2012 type-specific antibody avidity was poor (19.4 ± 10.7%). As expected, the avidity of GII.4 1999 immune serum against heterologous VLPs was considerably lower than type-specific avidity, but still at intermediate level (mean avidity indexes ranging from 30% to 40%). GII.4 1999 VLP immunization elicited cross-reactive antibodies against GII.4 2006 VLPs with significantly (p = 0.027) higher avidity than GII.4 2012 VLP immunization.
Blocking Antibody Responses
The ability of mouse immune sera to block homologous and heterologous VLPs binding to HBGAs present in human saliva (type A) was tested in a blocking assay [7, 40] . Both GII. 
Morphology, Antigenicity, and HBGA-Binding Profile of Genetically Engineered GII.4 2012 D310N VLPs
The NERK motif (amino acids 310, 316, 484, and 493, respectively) is suggested to control antibody access to epitope F, a putative universal blocking epitope in the GII.4 lineage [31] . We genetically engineered GII.4 2012 VLP to revert amino acid 310 from D to N, as present in GII.4 1999 VLP. The morphology of GII.4 2012 D310N VLPs was studied by electron microscopy, which confirmed that the mutation did not affect mutated VLP integrity or morphology (Figure 3a (Figure 3c ). HBGA binding assay against human saliva A, PGM, and synthetic carbohydrates confirmed that mutation D310N did not affect the ligand-binding abilities of the mutated VLPs (Figure 3d ). 
Blocking Antibody Responses against Genetically Engineered GII.4 2012 D310N VLPs
To study the effect of amino acid 310 mutation on cross-blocking activity we used GII. 
T-Cell Responses
ELISPOT IFN-γ was used to investigate whether there are differences in the development of homotypic or heterotypic T-cell immunity after GII. IFN-γ production was detected when un-pulsed BMDCs were used as a negative control (Figure 5d ). All samples were tested in duplicate cells. Cell viability of the responding cells was similar in all assays as controlled by Con A stimulation (data not shown). Background control (splenocytes in CM only) resulted in <40 spots per 10 6 cells. 
Discussion
An important issue in NoV VLP vaccine development is the antigenic diversity of NoV genotypes and the evolution of the predominant GII.4 strain resulting in variants able to escape herd immunity [5] . A similar phenomenon drives the antigenic drift of influenza virus, and therefore influenza vaccine must be reformulated on a yearly basis to match the circulating strains [16, 46] . The NoV VLP vaccine might also need to be reformulated every few years, or else cross-blocking epitopes could be induced to generate broadly blocking antibodies that protect against a variety of NoV variants [28, 30, 47] . In our earlier studies we have shown that ancestral GII.4 1999 VLPs tend to induce immune responses with better cross-reactivity and higher quality than other NoV genotype VLPs [48] [49] [50] Avidity of antibodies is considered to be an important surrogate of protective efficacy of several vaccines [51, 52] and high avidity enhances the cross-reactivity of antibodies by tolerating minor variation in the target epitopes [53] . In this study, only GII.4 1999 VLPs were able to induce type-specific antibodies with high avidity, whereas GII.4 2012 VLPs induced only antibodies with very low avidity. B cells that take up an antigen can either mature into extrafollicular plasmablasts secreting low-affinity antibodies or enter into germinal center (GC) where affinity maturation takes place with the help of follicular DCs and T-cells [54] . GII.4 1999 and GII.4 2012 VLPs may be differently uptaken or presented in GC affecting affinity maturation, but further studies are needed to confirm this notion. However, based on the results obtained here, antibody avidity cannot be considered as a single correlate of a strong blocking activity, as GII.4 2012 VLPs induced poor avidity antibodies but still conferred homologous blocking similarly to GII.4 1999 serum. Instead, high antiserum avidity may enhance the cross-neutralization ability as broadly neutralizing antiviral antibodies are usually detected in recurrent/chronic infections or after repeated vaccinations [55] .
We observed that GII.4 1999 immune serum had blocking activity against GII.4 2012 but not vice versa. The finding is in concordance with our earlier results where GII.4 1999 immune serum was able to block the VLP binding of another contemporary variant (GII.4 NO) to HBGAs whereas GII.4 NO immune serum completely lacked blocking activity against GII.4 1999 [48] . There might be several reasons as to why an ancestral GII.4 variant would induce blocking antibodies against a contemporary GII.4 variant but not vice versa. One potential explanation could be the surface structure of these VLPs. X-ray crystallography with murine NoVs has revealed that P-domains can be either in "open" or "closed" conformation [28] and some NoV VLPs are found in more epitope-accessible form than others [25] , giving reason to speculate as to whether such structural differences affect the immune responses generated in vivo. Hypothetically, better epitope-accessibility promotes the development of broadly blocking antibodies as conserved blocking epitopes tend to locate in more occluded than exposed parts of the NoV capsid [25, 47] and thus are not easily reached by B cell receptors. GII.4 2012 VLPs might be in a less epitope-accessible form than GII.4 1999 VLPs, explaining the different levels of humoral cross-reactivity induced. Possibly the evolution drives NoV to alter its structure to a more closed one to sterically protect the conserved epitopes, and therefore ancestral strains might be more suitable for the generation of cross-reactive immunity. However, additional studies are needed to evaluate the conformational differences and the epitope-accessibility between GII.4 variants. [23, 26] and 310 in the NERK motif [31] , shared between GII.4 1999 and GII.4 2006 VLPs might have greater impact on cross-blocking responses than other amino acids. In addition to blocking epitopes discussed here, other epitopes affecting the blocking responses have been published [28, 29] and there could be other yet undiscovered regions impacting the cross-blocking responses.
Broadly conserved epitopes are often occluded in the capsid and can be shielded by the virion via selected motifs regulating the exposition of these epitopes [27] . Epitope F in NoV GII.4 is an occluded, broadly conserved GII.4 blocking epitope, and the NERK motif is a potential conformational determinant regulating antibody access to epitope F [28, 31] . The NERK motif has remained unchanged among pandemic GII. VLPs and the effect on blocking activity of monoclonal antibody targeted to blocking epitope F was investigated [31] . As a result, mutated GII.4 NO (S310D) VLP blocking decreased (at max 4.1-fold) and in turn mutated GII.4 2012 (D310S) blocking increased (at max 3.2-fold) suggesting that serine (S) at position 310 indicates better access to the conserved blocking epitope F [31] . The difference with respect to our study was that we used polyclonal mouse serum instead of a monoclonal antibody generated against the single particular epitope. In contrast to cross-blocking activity, the D310N mutation did not have any effect on the homologous blocking activity of GII.4 2012 immune sera. This indicates that NERK motif-"guarded" F epitope is important specifically in cross-blocking responses, which supports earlier findings by others [30, 31] . The role of T-cell immunity in protection against NoV infection and disease is not well known but it might have a role in the generation of heterologous immunity [56, 57] . We and others have previously identified conserved NoV-specific CD4+ and CD8+ T-cell epitopes in mice [36, 49, 58] . Here, we were interested to see if the different potentials of GII.4 1999 and GII.4 2012 VLPs to induce cross-reactive antibodies were true also for T-cell responses. However, we did not detect a considerable difference in T-cell responses against any of the VLPs between GII.4 1999-and GII.4 2012-immunized mice. The results indicate that in the light of cross-reactivity, T-cell responses are quite distinct from B-cell responses and support earlier findings that T-cell responses are targeted to buried, broadly conserved epitopes in the NoV capsid [36, 49, 56, 58] . However, variation in the magnitude of the IFN-γ SFC between VLPs used for pulsing was detected. The highest number of IFN-γ-producing cells were detected with BMDCs pulsed with GII.4 1999 VLPs (regardless of the immunization), which suggests that GII.4 1999 VLPs could be uptaken and/or processed most efficiently by APCs.
We have previously proposed a candidate NoV VLP vaccine including GII.4 1999 and GI.3 VLPs [12] . The results of this study showed that GII.4 1999 VLP immunization induced higher-affinity antibodies with improved cross-reactive and cross-blocking properties in comparison to GII.4 2012 VLPs. The ability to elicit broad cross-reactive immunity is a key element of a successful NoV vaccine. We suggest that VLP structure (e.g., epitope accessibility), avidity of the antibodies and T-cell immunity might all play important role in heterologous NoV immunity and therefore should be considered in vaccine VLP selection. Based on the results of this study, and our earlier findings [48] [49] [50] , the ancestor GII.4 1999 VLPs have an intrinsic property of inducing antibodies with broad cross-reactivity and thus are good candidates for an NoV VLP vaccine. Funding: This research received no external funding.
